These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6890353)

  • 1. Fractionation of cold-sterilized plasma. A new concept in production of non-infectious plasma proteins.
    Stephan W
    Arzneimittelforschung; 1982; 32(8):799-801. PubMed ID: 6890353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII concentrate from cold sterilized human plasma.
    Stephan W; Prince AM; Kotitschke R
    Dev Biol Stand; 1983; 54():491-5. PubMed ID: 6418593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees.
    Prince AM; Stephan W; Brotman B; van den Ende MC
    Thromb Haemost; 1980 Dec; 44(3):138-42. PubMed ID: 7466740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative protein chemistry studies on Factor VIII concentrates].
    Kienast K; Trobisch H
    Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees.
    Stephan W; Kotitschke R; Prince AM; Brotman B
    Thromb Haemost; 1981 Aug; 46(2):511-4. PubMed ID: 7302890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and storage stability of proteins in a hepatitis-free human serum preparation.
    Stephan W
    Arzneimittelforschung; 1982; 32(8):802-6. PubMed ID: 6890354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).
    Heinrich D; Kotitschke R; Berthold H
    Thromb Res; 1982 Oct; 28(1):75-83. PubMed ID: 7157232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory and immunological profile of therapeutic serum protein solutions].
    Kotitschke R; Stephan W
    Infusionsther Klin Ernahr; 1985 Feb; 12(1):48-53. PubMed ID: 3886542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma fractionation in blood transfusion service.
    Haskó F; Salamon M; Bartha K; Dobó P
    Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and heat-treatment of factor-IX-concentrates.
    Stampe D; Wieland B; Köhle A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):523-7. PubMed ID: 2465966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.